Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib + Osimertinib in EGFR-Mutated Advanced Lung Cancer
NCT03891615Phase 1Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of niraparib in non-small cell lung cancer (NSCLC), sponsored by Massachusetts General Hospital. Primary endpoint: Maximum Tolerated Dose of Niraparib at 2 years. Started Jun 2019; status: terminated.
02
Drugs
niraparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03891615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03891615.